your market intelligence analyst
Search Results
204 results
Your search is now limited to «Hormone Therapy» expert search.
Hormonal therapies for osteoporosis management (eg, estrogens) are generally avoided in patients with hormonal-responsive cancers.
More from American Society of Clinical Oncolgy (ASCO):
PR Newswire 09/18/2019 02:12
By providing key information for early identification of those patients not responding or resistant to their on-going treatment, DiviTum® presents a non-invasive and efficacious approach to monitoring and predicting responses to standard hormonal therapies.
More from PR Newswire:
DoctorsLounge 09/17/2019 15:00
Looking at the data more closely, Spratt's team found that for men with low PSA blood levels after prostate surgery, long-term hormone therapy offered no cancer survival benefit, and was associated with a doubling of the risk that these men would die from causes other than their cancer.
More from DoctorsLounge: 09/17/2019 08:39
Initial results of NRG Oncology Clinical Trial RTOG 9601 in men with biochemically recurrent prostate cancer receiving salvage radiotherapy (SRT) demonstrated improvement in OS from the addition of long-term hormone therapy to SRT.
More from
Annals of Internal Medicine 09/16/2019 17:48
The researchers looked to see how the assigned treatment affected whether women developed heart disease, breast cancer, death from any cause, and a global score that took into consideration whether women developed these conditions in addition to stroke, blood clot to the lung, colon cancer, and hip fracture during the follow-up.
Healio News 09/16/2019 15:03
The higher the PSA, the more likely the patient was to benefit from hormone therapy because it decreased their chances of dying from prostate cancer and resulted in improved OS rates.
More from Healio News: 09/12/2019 07:48
This trial studies how well a text-based intervention works in improving adherence to hormone therapy in patients with stage I-III hormone receptor positive breast cancer.
More from
Forbes 09/11/2019 15:52
Johnson & Johnson (NYSE:JNJ) is the leader in the prostate cancer hormonal therapy market, with Zytiga sales of $3.5 billion in 2018. Other key drugs include Astellas’ Xtandi, and AbbVie’s Lupron. However, Zytiga could see a sharp decline in sales over the next few years, as it will face biosimil...
More from Forbes:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications